Mendus: Vididencel-induced anti-tumor immune responses in ovarian cancer

Mendus announced on Thursday that the company will present new clinical data on vididencel for ovarian cancer at the ESMO Gynaecological Cancers Annual Congress. The Phase I ALISON trial has met its primary objective of inducing tumor-directed immune responses in at least 10 patients (of 15) treated with vididencel. The company expects a primary read-out of the ALISON trial of all treated patients (17) in Q4’24.

10 patients showed tumor-directed immune responses following vididencel administration

ALISON is a Phase I clinical trial studying vididencel, Mendus’ cellular cancer immunotherapy, for ovarian cancer. The trial was fully enrolled with 17 patients as of April 2024. According to the new data, 10 out of 15 patients showed tumor-directed immune responses following vididencel administration. According to the announcement, 3 patients did not reach a vaccine-induced response (VIR) due to high baseline responses. In terms of adverse events, the results are in line with the previous understanding of vididencel having a very favorable safety/tolerability profile. The adverse events were mild and predominantly at the site of injection. At week 22 of the trial, 10 patients had stable disease and 7 had cancer recurrence confirmed by imaging. The ALISON trial will continue to follow up on the patients to gain more insight into the possible clinical benefit. Confirmation of whether vididencel leads to prolonged survival in patients with ovarian cancer still requires further research.

The new data will be presented at the ESMO Gynaecological Cancers Annual Congress, on June 20-22, 2024 in Florence, Italy. The poster will be available on Mendus’ website after the presentation.